| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 31 Aug 2026 | 24 Aug 2026 |
| Venmax Drugs And Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/08/2026 inter alia to consider and approve matters related to Annual General Meeting and any other business as the board deems fit to discuss with the permission of the chairman. Pursuant to Regulation 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015, we would like to inform you that a meeting of Board of Directors of was held today i.e August 31, 2026 at the registered office of the Company. (As per BSE Announcement dated on: 31.08.2026) | ||
| Board Meeting | 7 Aug 2026 | 1 Aug 2026 |
| Venmax Drugs And Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2026 inter alia to consider and approve Unaudited financial results for the quarter ended June 30 2026. Unaudited Standalone Financial Results along with the Limited Review Report For the Quarter ended June 30, 2026. Unaudited Financial Results along with Limited Review Report for the Quarter ended June 30, 2026. (As Per BSE Announcement Dated on:07.08.2026) | ||
| Board Meeting | 14 May 2026 | 6 May 2026 |
| Venmax Drugs And Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/05/2026 inter alia to consider and approve Audited Standalone Financial Results of the Company for the Quarter and Year ended March 31 2026. Audited Financial Results for the Quarter and Year ended March 31, 2026 Audited Financial Results for the Quarter and Year ended March 31 , 2026 (As Per BSE Annoncement Dated on:14.05.2026) | ||
| Board Meeting | 30 Mar 2026 | 30 Mar 2026 |
| The Board has considered and approved the appointment of Mrs. Padmaja Kalyani Sadhanala as an Additional director, Non Executive and Non Independent Director and Mr. Revoor Ramachandra as an Additional director, Non Executive Independent Director of the Company. | ||
| Board Meeting | 27 Mar 2026 | 27 Mar 2026 |
| Approval of Modification of draft Scheme of Amalgamation submitted on November 12, 2025 between Hatri Pharma Private Limited (Transferor Company) and Venmax Drugs and Pharmaceuticals Limited (Transferee Company) | ||
| Board Meeting | 23 Mar 2026 | 23 Mar 2026 |
| Allotment of 28,00,000 Convertible warrants in to Equity shares on preferential basis and pursuant to Regulation 30 read with Schedule III of SEBI LODR Regulations, 2015 | ||
| Board Meeting | 7 Feb 2026 | 30 Jan 2026 |
| Venmax Drugs And Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/02/2026 inter alia to consider and approve Unaudited Financial Results Of The Company For The Quarter Ended December 31 2025. Outcome of the Board Meeting held on Saturday, February 7, 2026, i.e, today, to consider and approve the Unaudited Financial Results For The Quarter And Nine Months Ended December 31, 2025. Unaudited Financial Results for the Quarter and Nine Months ended December 31, 2025. (As Per BSE Announcement Dated on:07.02.2026) | ||
| Board Meeting | 21 Jan 2026 | 21 Jan 2026 |
| The Board of directors at its meeting held today i.e. January 21, 2026 has approved the conversion of 7,75,000 share warrants in to Equity. | ||
| Board Meeting | 24 Nov 2025 | 24 Nov 2025 |
| The Board has considered and accepted the resignation of Mrs. Dakshita Jain as Non Executive Independent Director of the Company w.e.f. November 24, 2025. | ||
| Board Meeting | 12 Nov 2025 | 5 Nov 2025 |
| Venmax Drugs And Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2025 inter alia to consider and approve Unaudited Financial Results Of The Company For The Quarter Ended September 30 2025. Outcome of the Board Meeting held on Wednesday, November 12, 2025, i.e, today, to consider and approve the un-audited financial results for the quarter and half year ended September 30, 2025. (As Per Bse Announcement dated on 12/11/2025) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
